Objective: Our objective was to estimate the economic and humanistic burden among US adults with rheumatoid arthritis (RA).Methods: This study analyzed results from the Medical Expenditure Panel Survey from 2018 to 2020. Adults (aged ≥18 years) self‐reporting with RA or with the presence of the International Classification of Disease, 10th Revision clinical modification codes were identified. Healthcare expenditures (inpatient care, outpatient care, emergency department, office visits, prescription medications, home health, and others) were measured. The Short Form 12 Health Survey physical component summary (PCS), mental component summary (MCS), activities of daily living (ADL), and instrumental ADL (IADL) were measured. Two‐part models assessed the incremental increase in the health care expenditures for the RA group compared to the non‐RA group. In addition, the multivariable linear regression was used to evaluate the marginal difference in PCS and MCS between those with RA and those without RA, whereas the multivariable logistic regression models were used to evaluate the association between ADL and IADL by RA status.Results: Annually, 4.27 million adults with RA were identified. The two‐part model showed significantly higher total annual healthcare expenditures in the RA group than non‐RA group (mean $3,382.971 [95% confidence interval (CI) $1,816.50–$4,949.44]). Compared to the non‐RA group, the RA group was associated with lower PCS scores (mean 4.78 [95% CI 3.47–6.09]) and similarly lower MCS scores (mean −0.84 [95% CI −2.18 to 0.50]), as well as increased odds of requesting ADL (adjusted odds ratio [aOR] 2.02 [95% CI 1.59–2.56]) and IADL assistance (aOR 2.11 [95% CI 1.57–2.84]).Conclusion: RA was associated with higher health care expenditures, particularly prescription medication costs, and was associated with suboptimal quality of life.
Purpose:To determine whether pollen triggers urologic chronic pelvic pain syndrome (UCPPS) flares.Materials and Methods:We assessed flare status every two weeks for one year as part of the Multidis...
10 March 2022 in Diabetes Epidemiology and Management
Cholinesterase inhibitors (ChEIs) are recognized as first-line therapies for patients with mild-to-moderate dementia. However, there is limited comparative evidence regarding antipsychotic initiation risk among individual ChEIs to manage behavioral symptoms of dementia. This study aims to evaluate and compare the risk of antipsychotic initiation among dementia patients prescribed individual ChEIs. This is a retrospective cohort study using the 2009-2018 TriNetX electronic medical records data. Dementia patients aged over 60 years who were incident users of rivastigmine, donepezil, or galantamine with a 12-month washout period were included. Patients with a history of antipsychotic use during baseline and 30 days post-initiation of ChEIs were excluded. Patients were followed up to 12 months to identify the antipsychotic use. A generalized boosted model-based inverse probability treatment weights-adjusted Cox Proportional Hazard (CPH) model was applied to compare the risk of antipsychotic initiation across the different ChEIs. Among the 7,878 eligible dementia patients initiating ChEIs, 89.40% (n=7,043) were incident donepezil users, followed by 8.13% of (n=641) rivastigmine users, and 2.46% (n=194) galantamine users. During the 12-month follow-up, 807 patients (10.24%) initiated antipsychotics. The CPH model showed that rivastigmine users were at an increased risk of antipsychotic use compared to donepezil users (adjusted hazard ratio=1.45, 95% confidence interval: 1.11-1.88). No significant difference was observed in the risk of antipsychotic initiation between galantamine and donepezil users. This study found that rivastigmine users were more likely to initiate antipsychotics compared to donepezil users, while no significant difference between galantamine and donepezil users was observed. These findings emphasize the importance of careful medication monitoring and management to prevent prescribing cascades and reduce related adverse effects in dementia patients.